The COVID-19 pandemic
In spring 2020 the first lockdowns closed clinics and moved research staff to COVID-19 care. New patients per site fell by more than half worldwide in the worst month. Recovery came in months, with reversals in each new wave, and the shortage of research staff it left lasted for years.
- Pandemic wave, first national lockdown
- Headwind: new patients per site fell 59% globally in the trough month against the 2019 baseline (UK −87%, India −98%, US −45%, Spain −60%, France −77%, Germany −68%).What helped: Remote visits, direct-to-patient IMP, pausing non-essential screening, and protecting enrolled patients; oncology continued. What did not: Remote SDV (regulators diverged and sponsors reverted within months); the UK's non-COVID triage cost 44% of commercial recruitment. (SH-01, grade A)
- Pandemic recovery and second waves
- Partial recovery over 3 to 5 months with reversals: global −10% in July and −20% in August 2020; UK −40%, India −71%, US −22%, Spain +25% in August.What helped: Phased restart frameworks (NIHR levels); reducing recruitment before pausing. What did not: Staff attrition prolonged recovery; the winter wave cut SWOG enrolment 2% a week. (SH-02, grade A)
- Therapeutic-area sensitivity to a pandemic
- Oncology least hit (April −41%, baseline by June); cardiovascular −97%, respiratory −92%, endocrine −82%, dermatology −74% in April; control and prevention trials −73% against treatment trials −29% (SWOG).What helped: Prioritise trials where treatment cannot be deferred. What did not: Deferrable trials (prevention, dermatology) stayed depressed for months. (SH-03, grade A)
- Research-staff redeployment and burnout (long tail)
- Headwind for 2 to 3 years; coordinator shortages at 64.6% of sites; 80% of cancer centres with activation delays and 64% with declining accrual.What helped: Flexible working and retention measures; AACI turnover fell 29% from 2021 to 2022. What did not: Hiring inexperienced coordinators; a six-month cost per replacement is claimed by SCRS (anecdotal, no dataset). (SH-04, grade B)
- National research prioritisation during an emergency
- Headwind for non-priority studies: UK commercial recruitment −44% from 2017/18 to 2021/22; UK rank for trials initiated fell from 4th to 10th.What helped: Explicit triage protected the platform trials (RECOVERY and Solidarity). What did not: A reputational spiral of reduced allocations that had not reversed by 2022/23. (SH-05, grade A)
If it happens again
- Look after patients already in the study first: remote visits and medicine delivered to the home kept them on treatment and in follow-up.
- Expect the effect to differ by therapeutic area. Treatment that cannot wait, such as cancer care, recovered within months; prevention and deferrable studies stayed down far longer.
- Slow recruitment before pausing it, and restart in phases.
- Plan for a long staffing tail, not a quick rebound: coordinator shortages outlasted the lockdowns by two to three years.
Risk register SH-01 to SH-05: Medidata 20202; Unger et al. 2020 and 20212; O'Shaughnessy review 2023; Advarra 2025; AACI 2023